Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2009 Mar;94(3):310-2.
doi: 10.3324/haematol.2008.002329.

Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?

Jakob R Passweg, André Tichelli
Editorial

Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?

Jakob R Passweg et al. Haematologica. 2009 Mar.

Abstract

The combination of antithymocyte globulin of horse origin and cyclosporine A is the standard treatment for aplastic anemia in patients not eligible for bone marrow transplantation. In this perspective article, Drs. Passweg and Tichelli discuss the current immunosuppressive therapy of aplastic anemia. See related article on page 348.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival up to 10 years for patients (n=2400) with severe aplastic anemia treated with ATG reported to the European Group for Blood and Marrow Transplantation (EBMT) database having received ATG ± CSA as a first line treatment. Patients were treated between 1973–2007. Five-year survival probabilities are: 49± 7% for patients treated between 1973–1980 (n=178), 62 ± 3% for those treated between 1980–1990 (n=850), 74 ± 3% for patients treated between 1990–2000 (n=928) and 72 ± 6% for those treated between 2000–2007 (n=444).
See this image and copyright information in PMC

Comment on

References

    1. Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975;45:355–63. - PubMed
    1. Du X-Y, Pumbo E, Ivanovich J, An P, Maziarz RT, Reiss UM, et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood. 2009;113:309–16. - PMC - PubMed
    1. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy - the European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69–80. - PubMed
    1. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91–101. - PubMed
    1. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100:786–90. - PubMed

MeSH terms